Compare CSTE & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | ATNM |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 50.2M |
| IPO Year | 2012 | N/A |
| Metric | CSTE | ATNM |
|---|---|---|
| Price | $1.85 | $1.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | ★ 536.2K | 194.8K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $400,656,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | $42,943.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.86 | $1.03 |
| 52 Week High | $5.04 | $2.41 |
| Indicator | CSTE | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 71.24 | 51.02 |
| Support Level | $0.86 | $1.33 |
| Resistance Level | $1.94 | $1.54 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 92.08 | 56.90 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.